Current FDA approval of this adaptive system is for the treatment of Parkinson’s only, not essential tremor, dystonia (a ...

A photothermal, nanoparticle-based deep brain stimulation (DBS) system has successfully reversed the symptoms of Parkinson’s disease in laboratory mice. Under development by researchers in Beijing, ...

Mayo Clinic researchers have found a new way to more precisely detect and monitor brain cell activity during deep brain ...

On Feb 24, the FDA approved Medtronic’s BrainSense Adaptive deep brain stimulation, a device that surgeons implant in patients’ chests with electrodes connecting to the brain. The system is ...

However, there are lots of reasons for optimism: the treatment had a dramatic effect on the damage caused by the mouse model ... to expand the field of deep brain stimulation without the need ...

Researchers from Carnegie Mellon University and Allegheny Health Network have developed a new method for deep brain stimulation. The technique, called "DeepFocus," uses transcranial electrical ...

Case marks the beginning of a multi-site pivotal trial to evaluate Abbott’s system for management of treatment-resistant ...

While deep-brain stimulation has been available to patients for decades—through implants that send electric signals similar to how pacemakers connect with the heart—adaptive stimulation aims ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease. The FDA approved adaptive deep brain stimulation (aDBS ...

The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s disease. The new technology is expected to be available in the US later in 2025.